Search Results
Your search for 27 matches 3376 pages
Showing 2901 - 29502015 Oncology Meetings
FEBRUARY AACR-SNMMI Joint Conference: State-of-the-Art Molecular Imaging in Cancer Biology and TherapyFebruary 11-14 • San Diego, California For more information: www.aacr.org 2015 BMT Tandem Meeting American Society for Blood and Marrow TransplantationFebruary 11 - 15 • San Diego, California For...
Moffitt Cancer Center Reports on Faculty Participants in International Discovery of Genetic Risk Factors for Ovarian Cancer
Researchers from Moffitt Cancer Center in Tampa, Florida have participated in a global effort that has identified six new regions of the genome that increase risk of epithelial ovarian cancer, according to a news release from Moffitt. The collaborative study was published recently in Nature...
Novel Genomic Signature Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer
As reported in the Journal of the National Cancer Institute, Anirban P. Mitra, MD, PhD, of the University of Southern California, and colleagues identified a novel genome-based signature that improves prediction of postcystectomy recurrence in patients with high-risk bladder cancer.1 Use of the...
Ruxolitinib for Polycythemia Vera
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 4, 2014, ruxolitinib (Jakafi) was approved for the...
CAR T Cells Impressive in Acute Lymphocytic Leukemia
As more experience is gained with the use of genetically engineered chimeric antigen receptor (CAR) T cells in patients with leukemia, the data continue to be highly encouraging. Three different groups using slightly different modifications of CAR T cells reported positive experiences in treating...
Modified Nab-Paclitaxel/Gemcitabine in Pancreatic Cancer: Efficacious, Less Toxic, Less Costly
A less intensive regimen of nab-paclitaxel (Abraxane) plus gemcitabine appears to be as efficacious as the standard regimen in first-line treatment for metastatic pancreatic cancer, but less toxic and far less expensive, according to a study that earned a Merit Award at the 2015 Gastrointestinal...
Primary Surgical Therapy Results in Higher 5-Year Survival for Patients With Advanced-Stage Disease
Bucking national trends toward preserving the larynx in patients with advanced laryngeal cancer, treatment of patients for stage IV disease at Louisiana State University (LSU) Health-Shreveport were more likely to involve primary surgical therapy, including total laryngectomy, and more likely to...
2015 Oncology Meetings
FEBRUARY Genitourinary Cancers SymposiumFebruary 26-28 • Orlando, Florida For more information: www.gucasym.org 5th Annual Texas Adolescent and Young Adult Oncology ConferenceFebruary 27-28 • Houston, Texas For more information:...
Surgery Plus Immunotherapy Improves Survival in Melanoma Patients With Gastrointestinal Metastases
When melanoma patients develop metastases to the gastrointestinal (GI) tract or pancreas, resection of these lesions may improve survival, according to two single-institution studies presented at the 2015 Gastrointestinal Cancers Symposium. In a study that earned a Merit Award, researchers reported ...
High-Quality Diet Before Ovarian Cancer Diagnosis May Lengthen Survival
An overall high-quality diet at least 12 months before a diagnosis of ovarian cancer “was associated with a statistically significant 27% lower risk of death after ovarian cancer,” an analysis of dietary data from the Women’s Health Initiative showed. The protective effect was strongest among women ...
Theodore Lawrence, MD, PhD, Named Director of University of Michigan Comprehensive Cancer Center
Theodore S. Lawrence, MD, PhD, has been named Director of the University of Michigan Comprehensive Cancer Center. Dr. Lawrence succeeds Max S. Wicha, MD, who founded the Cancer Center 27 years ago. “This is a tremendous program, with talented and dedicated faculty and staff, a terrific research...
2015 Oncology Meetings
MARCH Advanced Prostate Cancer Consensus ConferenceMarch 12-14 • St. Gallen, Switzerland For more information: www.prostatecancerconsensus.org NCCN Annual Conference: Advancing the Standard of Cancer CareMarch 12-15 • Hollywood, Florida For more information:...
First-Line Crizotinib Improves Progression-Free Survival vs Chemotherapy in ALK-Positive NSCLC
In a phase III trial (PROFILE 1014) reported in The New England Journal of Medicine, Benjamin J. Solomon, MB, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues found that the ALK inhibitor crizotinib (Xalkori) improved progression-free survival vs standard chemotherapy in...
Nivolumab Shows Activity in Previously Treated Metastatic Renal Cell Carcinoma
In a randomized phase II trial reported in the Journal of Clinical Oncology, Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that the programmed cell death protein-1 (PD-1) immune checkpoint inhibitor antibody nivolumab (Opdivo) was associated with...
From ASH 2014: What’s New in the Myeloma Treatment Arsenal?
At the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, attendance at many multiple myeloma sessions outnumbered the room size, as data from studies of novel agents, such as the monoclonal antibodies, and from key trials, such as ASPIRE, drew crowds. The ASCO Post covered...
2015 Oncology Meetings
MARCH Personalised Cancer Medicine and Big Data Analysis – 7th International Conference of Contemporary OncologyMarch 25-27 • Poznań, Poland For more information: www.termedia.pl/Konferencje?Invitation&e=372&p=2787 Society of Surgical Oncology Annual MeetingMarch 25-28 • Houston, Texas For ...
Study Finds Websites That Market Personalized Cancer Care Services Overemphasize Benefits
A recent analysis of 55 Internet websites marketing a broad range of tests and services that promise the ability to personalize cancer treatment has found that the websites often overemphasize their purported benefits and downplay their limitations. In addition, the study results show that the...
Wrestling With the Challenges of Breast Cancer
Bookmark Title: Then Came Life: Living With Courage, Spirit, and Gratitude After Breast CancerAuthor: Geralyn LucasPublisher: Gotham BooksPublication date: October 2, 2014Price: $19.89; hardcover, 240 pages Over the past decade or so, the oncology community has increased its understanding and...
Adjuvant Chemotherapy Favored in Locally Advanced Bladder Cancer Not Treated With Neoadjuvant Therapy
A large observational study presented at the 2015 Genitourinary Cancers Symposium in Orlando, Florida, found that adjuvant chemotherapy extended the likelihood of survival in locally advanced bladder cancer compared with observation alone.1 Using three different approaches to propensity scores...
Antiangiogenesis Plus Chemotherapy Pursued in Advanced Bladder Cancer
Two separate phase II studies lend support to the concept of antiangiogenesis in advanced bladder cancer. The combination of an antiangiogenic agent and chemotherapy may fulfill an unmet need in this disease, the studies suggest. Both studies were presented at the 2015 Genitourinary Cancers...
Intensified Immunotherapy Encouraging in Chemotherapy-Naive Metastatic Prostate Cancer
Emerging evidence suggests that immunotherapy may play an important role in treating prostate cancer. In particular, preliminary results have shown that combining a new vaccine with ipilimumab (Yervoy) boosts overall survival in men with castration-resistant prostate cancer.1 A study comparing...
2015 Oncology Meetings
APRIL Melanoma and Cutaneous Malignancies MeetingApril 10-11 • New York, New York For more information: www.healio.com/meeting/hemonctodaymelanoma/home?promocode689-8045 Hematologic Malignancies: New Therapies and the Evolving Role of TransplantApril 10-11 • Chicago, Illinois For more information: ...
Nivolumab in Metastatic Squamous Non–Small Cell Lung Cancer After Platinum Therapy
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 4, 2015, the anti–programmed cell death protein 1 (PD-1) ...
The ASPIRE Trial of Carfilzomib in Relapsed Myeloma: A Major Step Forward
Currently in myeloma, there are at least five new agents that are either approved or in the late-stage of development with impending approval. Major questions in the field relate to how we, as clinicians, will use these new agents and where they will fit in the overall treatment schema. The phase...
Increased Progression-Free Survival With Addition of Carfilzomib to Lenalidomide/Dexamethasone in Relapsed Multiple Myeloma
In a planned interim analysis of the phase III ASPIRE trial reported in The New England Journal of Medicine, A. Keith Stewart, MB, ChB, of the Mayo Clinic, Scottsdale, Arizona, and colleagues found that the addition of the proteasome inhibitor carfilzomib (Kyprolis) to lenalidomide...
Researchers and Scientists Honored for Improving Cancer Prevention, Treatment, and Patient Care
The ASCO Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology community to enhancing cancer prevention, treatment, and patient care. Among this year’s awardees are an international leader in geriatric oncology...
No Survival Benefit From Adjuvant Sorafenib or Sunitinib in Kidney Cancer
Adjuvant therapy with sorafenib (Nexavar) or sunitinib (Sutent) failed to make any inroads in improving disease-free survival in patients with locally advanced kidney cancer in the randomized, placebo-controlled, multicenter, phase III Adjuvant Sorafenib and Sunitinib for Unfavorable Renal...
The ASCO Post Replies
Nivolumab (Opdivo) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of lung cancer on March 4, 2015, before clinical data from the pivotal trials (CheckMate 017 and CheckMate 063) were presented at a major oncology conference or published in a peer-reviewed journal....
Objective Response Rate of 44% Among Patients With Relapsed/Refractory DLBCL Receiving Brentuximab Vedotin
A phase II, open-label study evaluating the efficacy of brentuximab vedotin (Adcetris), an anti-CD antibody-drug conjugate, found that among 48 evaluable patients with CD30-positive diffuse large B-cell lymphoma (DLBCL), 21 (44%) had objective responses. These responses included 8 patients (17%)...
2015 Oncology Meetings
MAY International Society of Geriatric Oncology (SIOG): Cancer Care of the Older Adult Across the Cancer ContinuumMay 1 • New York, New York For more information: www.siog.org 1st Annual New Treatments in Oncology Conference (ANTO)May 1-2 • Scottsdale, Arizona For more information:...
Too Young to Have Cancer
The first inkling I had that something could be seriously wrong occurred just over a year ago, when I was suddenly inflicted with such severe heartburn it kept me awake at night. Prescriptions from my doctor for ranitidine (Zantac) and meloxicam (Mobic) not only failed to tamp down the fiery pain,...
Staff Support Sessions in an Oncology Setting
Work-related issues such as coping skills, stress management, burnout, and compassion fatigue are among the challenges faced by clinical and other staff in cancer treatment centers. Given the emotional consequences of professional caregiving, staff support group meetings are valuable resources for...
Overweight Girls Face Increased Risk of Colorectal Cancer Later in Life
Girls who are overweight as young children and teens may face increased risk for colorectal cancer decades later, regardless of what they weigh as adults, suggests a new study published by Xuehong Zhang, MD, ScD, Instructor at Harvard Medical School, and colleagues in Cancer Epidemiology,...
Should We Be Worried If Patients Tolerate Endocrine Therapy Well?
When meeting with patients to discuss adjuvant endocrine therapy for breast cancer, the question often arises, “How will I know that the treatment is working?” While the efficacy of these treatments has been demonstrated for the majority of patients in multiple large randomized clinical trials,...
Analysis Shows No Link Between Aromatase Inhibitor–Related Musculoskeletal/Vasomotor Symptoms and Relapse-Free Survival
Retrospective analyses of the ATAC, TEAM, and BIG 1-98 adjuvant endocrine therapy trials in breast cancer have suggested that treatment-emergent endocrine symptoms may be associated with superior survival outcomes. In a study reported in the Journal of Clinical Oncology, Vered Stearns, MD,...
2015 Oncology Meetings
MAY 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)May 11-13 • Mainz, Germany For more information: www.meeting.cimt.eu 54th Annual Conference of the Particle Therapy Co-Operative GroupMay 18-23 • San Diego, California For more information: http://ptcog54.org American...
Impact of Informed Decision-Making on Breast Cancer Screening
In a study reported in Lancet, Jolyn Hersch, MApplSc, of the University of Sydney, and colleagues found that use of a decision aid containing information on overdetection in breast cancer screening was associated with an increased rate of informed choice regarding screening, a reduced rate of...
People Living With HIV in the United States Have a 50% Excess Cancer Risk
The nearly 900,000 people in the United States living with diagnosed human immunodeficiency virus (HIV) infection have an excess cancer risk of 50%, according to a joint analysis of data by the National Cancer Institute and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention,...
Therapy for Hepatitis C Virus Infection in Patients With Cancer May Prevent Liver Disease Progression
“Hepatitis C virus (HCV) infection is a neglected disease in patients with cancer,” Harrys A. Torres, MD, and colleagues from the University of Texas MD Anderson Cancer Center in Houston noted in the Journal of the National Comprehensive Cancer Network. To rectify that situation, the researchers...
Just Engaging in ‘Some’ Leisure Time Physical Activity Reduces Overall and Cancer-Specific Mortality
There’s good news for those who recognize the benefits of exercise but feel they have neither the time nor energy for frequent workouts: A recent study reported in JAMA Internal Medicine1 has found that just performing “some” leisure time physical activity, even below the recommended minimum level, ...
2015 Oncology Meetings
MAY American Association for Cancer Research: Advances in Brain Cancer ResearchMay 27-30 • Washington, DC For more information: www.aacr.org ASCO Annual MeetingMay 29-June 2 • Chicago, Illinois For more information: am.asco.org 2015 ASCO State Affiliates’ ReceptionMay 31 • Chicago, Illinois For...
Ramucirumab With FOLFIRI in Metastatic Colorectal Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 24, the monoclonal antibody ramucirumab (Cyramza) was...
Meaning-Centered Group Psychotherapy Improves Psychological Well-Being in Patients With Advanced Cancer
In a randomized trial reported in the Journal of Clinical Oncology, William Breitbart, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that meaning-centered group psychotherapy significantly improved psychological well-being compared with supportive group psychotherapy in...
High Invasive Disease-Free Survival With Adjuvant Paclitaxel and Trastuzumab in Small, Node‑Negative, HER2-Positive Breast Cancers
In a phase II study reported in The New England Journal of Medicine, Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that adjuvant paclitaxel and trastuzumab (Herceptin) was associated with high invasive disease-free survival in women with small, node-negative,...
Increased Risk of Secondary Bone Marrow Neoplasia After Adjuvant Breast Cancer Treatment: Risk/Benefit Analysis and Biologic Insights
Ever since the early application of adjuvant chemotherapy for breast cancer decades ago, it has been recognized that there is always a price to pay for its success in reducing breast cancer mortality. Most of that “cost” is commonly considered in terms of the potential morbid short- and long-term...
Higher-Than-Expected Incidence of Marrow Neoplasms After Adjuvant Therapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues found a low but higher-than-expected incidence of marrow neoplasms in patients receiving adjuvant radiation therapy or chemotherapy...
Addition of Lenalidomide to Docetaxel-Prednisone Worsens Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
In the phase III MAINSAIL trial reported in The Lancet Oncology, Daniel P. Petrylak, MD, of Yale Cancer Center, New Haven, Connecticut, and colleagues found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate...
Answers: Case Report on Chronic Myelogenous Leukemia
Question 1: In the current era of tyrosine kinase inhibitor therapy, which prognostic model is best to assess the prognosis of a person with a new diagnosis of CML? Correct Answer: D. All of the above Expert Perspective Despite not being perfect, all of these scores are reasonably effective at...
HPV-Related Anal Cancer on the Rise
More than 7,200 cases of anal cancer were diagnosed in 2014—approximately 2,600 in men and 4,600 in women—representing an increase of more than 4,000 from 8 years ago. In more than 90% of patients, infection with the human papillomavirus (HPV) is the cause, tagging anal cancer as a largely...
Novel Agent Elotuzumab Added to Lenalidomide/Dexamethasone Extends Progression-Free Survival in Multiple Myeloma
The monoclonal antibody elotuzumab, given with lenalidomide (Revlimid) and dexamethasone, extended progression-free survival by a median of 5 months, compared with lenalidomide/dexamethasone alone, in the eagerly awaited phase III ELOQUENT-2 trial, which will be presented at the 2015 ASCO Annual...
